<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01592162</url>
  </required_header>
  <id_info>
    <org_study_id>2011/34</org_study_id>
    <secondary_id>2011-002644-27</secondary_id>
    <nct_id>NCT01592162</nct_id>
  </id_info>
  <brief_title>Comparison of Different Propofol Formulations With or Without Remifentanil</brief_title>
  <acronym>PropofolRemi</acronym>
  <official_title>Dose-effect of Propofol for Anesthetic Induction: Double-blind Comparison of Different Propofol Formulations Administered Alone or With Remifentanil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the influence of different propofol formulations
      (plain or with remifentanil) on anesthetic induction. Propofol plain or with remifentanil is
      administered using a closed-loop algorithm in order to reach a Bispectral Index target of 50.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>necessary dose of propofol to obtain the induction of anesthesia (defined by a bispectral index &lt; 60 over 30 continuous seconds)</measure>
    <time_frame>one hour after anesthesia</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>calculated concentrations of propofol at the end of the anesthetic induction</measure>
    <time_frame>one hour after anesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain at injection</measure>
    <time_frame>one hour after anesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate modifications induced by anesthetic induction</measure>
    <time_frame>one hour after anesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient's satisfaction</measure>
    <time_frame>one day after anesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial pressure modifications induced by anesthetic induction</measure>
    <time_frame>one hour after anesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance of the eyelash reflex</measure>
    <time_frame>One hour after anesthesia</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">409</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>propofol 1% (Astra-Zeneca) - remi 0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>propofol 1% (Astra-Zeneca)plus remifentanil 0 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol 1% (Astra-Zeneca) - remi 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>propofol 1% (Astra-Zeneca)plus remifentanil 2 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol 1% (Astra-Zeneca) - remi 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>propofol 1% (Astra-Zeneca)plus remifentanil 4 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol 1% (Fresenius) - remi 0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>propofol 1% (Fresenius) plus remifentanil 0 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol 1% (Fresenius) - remi 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>propofol 1% (Fresenius) plus remifentanil 2 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol 1% (Fresenius) - remi 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>propofol 1% (Fresenius) plus remifentanil 4 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol 1% (B-Braun) - remi 0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>propofol 1% (B-Braun) plus remifentanil 0 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol 1% (B-Braun) - remi 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>propofol 1% (B-Braun) plus remifentanil 2 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol 1% (B-Braun) - remi 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>propofol 1% (B-Braun) plus remifentanil 4 ng/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol (Astra-Zeneca), NaCl 0.9%</intervention_name>
    <description>propofol administered by a closed-loop system and saline</description>
    <arm_group_label>propofol 1% (Astra-Zeneca) - remi 0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol 1% (Astra-Zeneca) and remifentanil</intervention_name>
    <description>propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)</description>
    <arm_group_label>propofol 1% (Astra-Zeneca) - remi 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol 1% (Astra-Zeneca) and remifentanil</intervention_name>
    <description>propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)</description>
    <arm_group_label>propofol 1% (Astra-Zeneca) - remi 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol (Astra-Zeneca), NaCl 0.9%</intervention_name>
    <description>propofol administered by a closed-loop system and saline</description>
    <arm_group_label>propofol 1% (Fresenius) - remi 0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol (Astra-Zeneca) and remifentanil</intervention_name>
    <description>propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)</description>
    <arm_group_label>propofol 1% (Fresenius) - remi 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol (Astra-Zeneca) and remifentanil</intervention_name>
    <description>propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)</description>
    <arm_group_label>propofol 1% (Fresenius) - remi 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol (B-Braun) and NaCl 0.9%</intervention_name>
    <description>propofol administered by a closed-loop system and saline</description>
    <arm_group_label>propofol 1% (B-Braun) - remi 0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol (B-Braun) and remifentanil</intervention_name>
    <description>propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)</description>
    <arm_group_label>propofol 1% (B-Braun) - remi 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol (B-Braun) and remifentanil</intervention_name>
    <description>propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)</description>
    <arm_group_label>propofol 1% (B-Braun) - remi 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for an intravenous induction of anesthesia with propofol

        Exclusion Criteria:

          -  Age under 18

          -  Pregnancy or breastfeeding

          -  Allergy to propofol, soya or peanuts,

          -  Allergy to remifentanil,

          -  History of central neurological disorder or brain injury,

          -  Patients receiving psychotropic drugs,

          -  Patient with a pacemaker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Fischler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <state>Ile de France</state>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2012</study_first_submitted>
  <study_first_submitted_qc>May 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2012</study_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

